Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease

Neurochemistry International

Volumn 61, Issue 6, 2012, Pages 899-906

  Braithwaite, Steven P ^a   Voronkov, Michael ^a   Stock, Jeffry B ^a,b   Mouradian, M Maral ^c  

^a Signum Biosciences Inc   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Alpha synucleinopathies; Kinases; Neurodegeneration; Neuroprotection; Parkinson's disease; Phosphorylation; PP2A; Protein aggregation; Protein phosphatase

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ALPHA SYNUCLEIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASEIN KINASE I; CASEIN KINASE II; CEP 1347; CERAMIDE; EICOSANOYL 5 HYDROXYTRYPTAMIDE; G PROTEIN RECEPTOR COUPLED KINASE 1; G PROTEIN RECEPTOR COUPLED KINASE 2; G PROTEIN RECEPTOR COUPLED KINASE 5; G PROTEIN RECEPTOR COUPLED KINASE 6; IMATINIB; LEUCINE RICH REPEAT KINASE 2; MICROCYSTIN; PHOSPHATASE; PHOSPHATASE AND TENSIN INDUCED HOMOLOG KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOTRANSFERASE; POLO LIKE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RECEPTOR TYROSINE PHOSPHATASE BETA; RECEPTOR TYROSINE PHOSPHATASE EPSILON; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CONFERENCE PAPER; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; ENZYME ACTIVITY; GENE MUTATION; GENETIC LINKAGE; HUMAN; LEWY BODY; NEURITE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

HUMANS; MUTATION; PARKINSON DISEASE; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 84864073236     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.01.031     Document Type: Conference Paper

References (112)

1. A. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal, and K. Iqbal Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments Proc. Natl. Acad. Sci. USA 98 2001 6923 6928
2. J.P. Anderson, D.E. Walker, J.M. Goldstein, R. de Laat, K. Banducci, R.J. Caccavello, R. Barbour, J. Huang, K. Kling, M. Lee, L. Diep, P.S. Keim, X. Shen, T. Chataway, M.G. Schlossmacher, P. Seubert, D. Schenk, S. Sinha, W.P. Gai, and T.J. Chilcote Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease J. Biol. Chem. 281 2006 29739 29752
3. K. Arima, S. Hirai, N. Sunohara, K. Aoto, Y. Izumiyama, K. Ueda, K. Ikeda, and M. Kawai Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies Brain Res. 843 1999 53 61
4. S. Azeredo da Silveira, B.L. Schneider, C. Cifuentes-Diaz, D. Sage, T. Abbas-Terki, T. Iwatsubo, M. Unser, and P. Aebischer Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease Human Mol. Genet. 18 2009 872 887
5. D.A. Bachovchin, J.T. Mohr, A.E. Speers, C. Wang, J.M. Berlin, T.P. Spicer, V. Fernandez-Vega, P. Chase, P.S. Hodder, S.C. Schurer, D.K. Nomura, H. Rosen, G.C. Fu, and B.F. Cravatt Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors Proc. Natl. Acad. Sci. USA 108 2011 6811 6816
6. A. Beilina, M. Van Der Brug, R. Ahmad, S. Kesavapany, D.W. Miller, G.A. Petsko, and M.R. Cookson Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability Proc. Natl. Acad. Sci. USA 102 2005 5703 5708
7. H. Bergman, and G. Deuschl Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back Mov. Disord. 17 Suppl. 3 2002 S28 S40
8. D. Blum, S. Torch, N. Lambeng, M. Nissou, A.L. Benabid, R. Sadoul, and J.M. Verna Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease Prog. Neurobiol. 65 2001 135 172
9. J. Bras, A. Singleton, M.R. Cookson, and J. Hardy Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease FEBS J. 275 2008 5767 5773
10. A.M. Brown, A.J. Baucum, M.A. Bass, and R.J. Colbran Association of protein phosphatase 1 gamma 1 with spinophilin suppresses phosphatase activity in a Parkinson disease model J. Biol. Chem. 283 2008 14286 14294
11. A.M. Brown, A.Y. Deutch, and R.J. Colbran Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism Eur. J. Neurosci. 22 2005 247 256
12. C.E. Chalfant, Z. Szulc, P. Roddy, A. Bielawska, and Y.A. Hannun The structural requirements for ceramide activation of serine-threonine protein phosphatases J. Lipid Res. 45 2004 496 506
13. J.W. Chambers, A. Pachori, S. Howard, M. Ganno, D. Hansen Jr.; T. Kamenecka, X. Song, D. Duckett, W. Chen, Y.Y. Ling, L. Cherry, M.D. Cameron, L. Lin, C.H. Ruiz, and P. Lograsso Small molecule c-jun-N-terminal kinase (JNK) inhibitors protect dopaminergic neurons in a model of Parkinson's disease ACS Chem. Neurosci. 2 2011 198 206
14. M.C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, S. Lincoln, C. Levecque, L. Larvor, J. Andrieux, M. Hulihan, N. Waucquier, L. Defebvre, P. Amouyel, M. Farrer, and A. Destee Alpha-synuclein locus duplication as a cause of familial Parkinson's disease Lancet 364 2004 1167 1169
15. C.L. Chen, C.F. Lin, C.W. Chiang, M.S. Jan, and Y.S. Lin Lithium inhibits ceramide- and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis Mol. Pharmacol. 70 2006 510 517
16. L. Chen, and M.B. Feany Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease Nat. Neurosci. 8 2005 657 663
17. M.O. Chohan, S. Khatoon, I.G. Iqbal, and K. Iqbal Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine FEBS Lett. 580 2006 3973 3979
18. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, K. Tiel-Wilck, A. de Vera, J. Jin, T. Stites, S. Wu, S. Aradhye, and L. Kappos Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N. Engl. J. Med. 362 2010 402 415
19. N.M. Corcoran, C.M. Hovens, M. Michael, M.A. Rosenthal, and A.J. Costello Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer Br. J. Cancer 103 2010 462 468
20. J.M. Cunnick, S. Meng, Y. Ren, C. Desponts, H.G. Wang, J.Y. Djeu, and J. Wu Regulation of the mitogen-activated protein kinase signaling pathway by SHP2 J. Biol. Chem. 277 2002 9498 9504
21. X. Deng, N. Dzamko, A. Prescott, P. Davies, Q. Liu, Q. Yang, J.D. Lee, M.P. Patricelli, T.K. Nomanbhoy, D.R. Alessi, and N.S. Gray Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 7 2011 203 205
22. R.T. Dobrowsky, C. Kamibayashi, M.C. Mumby, and Y.A. Hannun Ceramide activates heterotrimeric protein phosphatase 2A J. Biol. Chem. 268 1993 15523 15530
23. Durgadoss, L.; Nidadavolu, P.; Khader Valli, R.; Saeed, U.; Mishra, M.; Seth, P.; Ravindranath, V.; 2011. Redox modification of Akt mediated by the dopaminergic neurotoxin MPTP, in mouse midbrain, leads to down-regulation of pAkt. FASEB J.
24. S. Elmore Apoptosis: a review of programmed cell death Toxicol. Pathol. 35 2007 495 516
25. C. Fiorentini, C. Mattanza, G. Collo, P. Savoia, P. Spano, and C. Missale The tyrosine phosphatase Shp-2 interacts with the dopamine D(1) receptor and triggers D(1)-mediated Erk signaling in striatal neurons J. Neurochem. 117 2011 253 263
26. E.A. Foley, M. Maldonado, and T.M. Kapoor Formation of stable attachments between kinetochores and microtubules depends on the B56-PP2A phosphatase Nat. Cell. Biol. 13 2011 1265 1271
27. H. Fujiwara, M. Hasegawa, N. Dohmae, A. Kawashima, E. Masliah, M.S. Goldberg, J. Shen, K. Takio, and T. Iwatsubo Alpha-synuclein is phosphorylated in synucleinopathy lesions Nat. Cell. Biol. 4 2002 160 164
28. F. Gillardon Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in parkinsonian neurodegeneration? J. Neurochem. 110 2009 1514 1522
29. C.J. Gloeckner, A. Schumacher, K. Boldt, and M. Ueffing The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro J. Neurochem. 109 2009 959 968
30. O.S. Gorbatyuk, S. Li, L.F. Sullivan, W. Chen, G. Kondrikova, F.P. Manfredsson, R.J. Mandel, and N. Muzyczka The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease Proc. Natl. Acad. Sci. USA 105 2008 763 768
31. G. Herradon, and L. Ezquerra Blocking receptor protein tyrosine phosphatase beta/zeta: a potential therapeutic strategy for Parkinson's disease Curr. Med. Chem. 16 2009 3322 3329
32. H. Hida, C.G. Jung, C.Z. Wu, H.J. Kim, Y. Kodama, T. Masuda, and H. Nishino Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro Eur. J. Neurosci. 17 2003 2127 2134
33. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 2009 382 397
34. P. Ibanez, A.M. Bonnet, B. Debarges, E. Lohmann, F. Tison, P. Pollak, Y. Agid, A. Durr, and A. Brice Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease Lancet 364 2004 1169 1171
35. Y. Imai, S. Gehrke, H.Q. Wang, R. Takahashi, K. Hasegawa, E. Oota, and B. Lu Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila EMBO J. 27 2008 2432 2443
36. K.J. Inglis, D. Chereau, E.F. Brigham, S.S. Chiou, S. Schobel, N.L. Frigon, M. Yu, R.J. Caccavello, S. Nelson, R. Motter, S. Wright, D. Chian, P. Santiago, F. Soriano, C. Ramos, K. Powell, J.M. Goldstein, M. Babcock, T. Yednock, F. Bard, G.S. Basi, H. Sham, T.J. Chilcote, L. McConlogue, I. Griswold-Prenner, and J.P. Anderson Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system J. Biol. Chem. 284 2009 2598 2602
37. M. Jaleel, R.J. Nichols, M. Deak, D.G. Campbell, F. Gillardon, A. Knebel, and D.R. Alessi LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity Biochem. J. 405 2007 307 317
38. V. Janssens, and J. Goris Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling Biochem. J. 353 2001 417 439
39. M. Kong, C.J. Fox, J. Mu, L. Solt, A. Xu, R.M. Cinalli, M.J. Birnbaum, T. Lindsten, and C.B. Thompson The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis Science 306 2004 695 698
40. R. Kruger, W. Kuhn, T. Muller, D. Woitalla, M. Graeber, S. Kosel, H. Przuntek, J.T. Epplen, L. Schols, and O. Riess Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat. Genet. 18 1998 106 108
41. U. Kumari, and E.K. Tan LRRK2 in Parkinson's disease: genetic and clinical studies from patients FEBS J. 276 2009 6455 6463
42. Y.C. Kuo, K.Y. Huang, C.H. Yang, Y.S. Yang, W.Y. Lee, and C.W. Chiang Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt J. Biol. Chem. 283 2008 1882 1892
43. B.D. Lee, J.H. Shin, J. VanKampen, L. Petrucelli, A.B. West, H.S. Ko, Y.I. Lee, K.A. Maguire-Zeiss, W.J. Bowers, H.J. Federoff, V.L. Dawson, and T.M. Dawson Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease Nat. Med. 16 2010 998 1000
44. J. Lee, Y. Chen, T. Tolstykh, and J. Stock A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain Proc. Natl. Acad. Sci. USA 93 1996 6043 6047
45. J. Lee, and J. Stock Protein phosphatase 2A catalytic subunit is methyl-esterified at its carboxyl terminus by a novel methyltransferase J. Biol. Chem. 268 1993 19192 19195
46. K.W. Lee, W. Chen, E. Junn, J.Y. Im, H. Grosso, P.K. Sonsalla, X. Feng, N. Ray, J.R. Fernandez, Y. Chao, E. Masliah, M. Voronkov, S.P. Braithwaite, J.B. Stock, and M.M. Mouradian Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model J. Neurosci. 31 2011 6963 6971
47. Y. Li, W. Liu, T.F. Oo, L. Wang, Y. Tang, V. Jackson-Lewis, C. Zhou, K. Geghman, M. Bogdanov, S. Przedborski, M.F. Beal, R.E. Burke, and C. Li Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease Nat. Neurosci. 12 2009 826 828
48. Y.S. Li, P.G. Milner, A.K. Chauhan, M.A. Watson, R.M. Hoffman, C.M. Kodner, J. Milbrandt, and T.F. Deuel Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity Science 250 1990 1690 1694
49. F. Liu, I. Grundke-Iqbal, K. Iqbal, and C.X. Gong Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation Eur. J. Neurosci. 22 2005 1942 1950
50. Z. Liu, X. Wang, Y. Yu, X. Li, T. Wang, H. Jiang, Q. Ren, Y. Jiao, A. Sawa, T. Moran, C.A. Ross, C. Montell, and W.W. Smith A Drosophila model for LRRK2-linked parkinsonism Proc. Natl. Acad. Sci. USA 105 2008 2693 2698
51. S. Longin, K. Zwaenepoel, J.V. Louis, S. Dilworth, J. Goris, and V. Janssens Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic Subunit J. Biol. Chem. 282 2007 26971 26980
52. Lou, H.; Montoya, S.E.; Alerte, T.N.; Wang, J.; Wu, J.; Peng, X.M.; Hong, C.S.; Friedrich, E.E.; Mader, S.A.; Pedersen, C.J.; Marcus, B.S.; McCormack, A.L.; Di Monte, D.A.; Daubner, S.C.; Perez, R.G.; 2010. Serine 129 phosphorylation reduces {alpha}-synuclein's ability to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J. Biol. Chem.
53. C. Malagelada, Z.H. Jin, and L.A. Greene RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation J. Neurosci. 28 2008 14363 14371
54. D.M. Marchionini, E. Lehrmann, Y. Chu, B. He, C.E. Sortwell, K.G. Becker, W.J. Freed, J.H. Kordower, and T.J. Collier Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease Brain Res. 1147 2007 77 88
55. Y. Matsuoka, Y. Nagahara, M. Ikekita, and T. Shinomiya A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells Br. J. Pharmacol. 138 2003 1303 1312
56. M.K. Mbefo, K.E. Paleologou, A. Boucharaba, A. Oueslati, H. Schell, M. Fournier, D. Olschewski, G. Yin, M. Zweckstetter, E. Masliah, P.J. Kahle, H. Hirling, and H.A. Lashuel Phosphorylation of synucleins by members of the Polo-like kinase family J. Biol. Chem. 285 2010 2807 2822
57. N.R. McFarland, Z. Fan, K. Xu, M.A. Schwarzschild, M.B. Feany, B.T. Hyman, and P.J. McLean Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease J. Neuropathol. Exp. Neurol. 68 2009 515 524
58. H.L. Melrose, J.C. Dachsel, B. Behrouz, S.J. Lincoln, M. Yue, K.M. Hinkle, C.B. Kent, E. Korvatska, J.P. Taylor, L. Witten, Y.Q. Liang, J.E. Beevers, M. Boules, B.N. Dugger, V.A. Serna, A. Gaukhman, X. Yu, M. Castanedes-Casey, A.T. Braithwaite, S. Ogholikhan, N. Yu, D. Bass, G. Tyndall, G.D. Schellenberg, D.W. Dickson, C. Janus, and M.J. Farrer Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice Neurobiol. Dis. 40 2010 503 517
59. K. Meng, A. Rodriguez-Pena, T. Dimitrov, W. Chen, M. Yamin, M. Noda, and T.F. Deuel Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta Proc. Natl. Acad. Sci. USA 97 2000 2603 2608
60. A. Mukhopadhyay, S.A. Saddoughi, P. Song, I. Sultan, S. Ponnusamy, C.E. Senkal, C.F. Snook, H.K. Arnold, R.C. Sears, Y.A. Hannun, and B. Ogretmen Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling FASEB J. 23 2009 751 763
61. R.J. Nichols, N. Dzamko, J.E. Hutti, L.C. Cantley, M. Deak, J. Moran, P. Bamborough, A.D. Reith, and D.R. Alessi Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease Biochem. J. 424 2009 47 60
62. U. Norinder, and M. Haeberlein Computational approaches to the prediction of the blood-brain distribution Adv. Drug Deliv. Rev. 54 2002 291 313
63. E. Ohta, F. Kawakami, M. Kubo, and F. Obata LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations FEBS Lett. 585 2011 2165 2170
64. M. Okochi, J. Walter, A. Koyama, S. Nakajo, M. Baba, T. Iwatsubo, L. Meijer, P.J. Kahle, and C. Haass Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein J. Biol. Chem. 275 2000 390 397
65. J.V. Olsen, B. Blagoev, F. Gnad, B. Macek, C. Kumar, P. Mortensen, and M. Mann Global, in vivo, and site-specific phosphorylation dynamics in signaling networks Cell 127 2006 635 648
66. C. Paisan-Ruiz, S. Jain, E.W. Evans, W.P. Gilks, J. Simon, M. van der Brug, A. Lopez de Munain, S. Aparicio, A.M. Gil, N. Khan, J. Johnson, J.R. Martinez, D. Nicholl, I.M. Carrera, A.S. Pena, R. de Silva, A. Lees, J.F. Marti-Masso, J. Perez-Tur, N.W. Wood, and A.B. Singleton Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 44 2004 595 600
67. K.E. Paleologou, A. Oueslati, G. Shakked, C.C. Rospigliosi, H.Y. Kim, G.R. Lamberto, C.O. Fernandez, A. Schmid, F. Chegini, W.P. Gai, D. Chiappe, M. Moniatte, B.L. Schneider, P. Aebischer, D. Eliezer, M. Zweckstetter, E. Masliah, and H.A. Lashuel Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions J. Neurosci. 30 2010 3184 3198
68. K.E. Paleologou, A.W. Schmid, C.C. Rospigliosi, H.Y. Kim, G.R. Lamberto, R.A. Fredenburg, P.T. Lansbury Jr.; C.O. Fernandez, D. Eliezer, M. Zweckstetter, and H.A. Lashuel Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein J. Biol. Chem. 283 2008 16895 16905
69. J. Pan, J. Qian, Y. Zhang, J. Ma, G. Wang, Q. Xiao, S. Chen, and J. Ding Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway Lab. Invest. 90 2009 156 167
70. L. Parisiadou, C. Xie, H.J. Cho, X. Lin, X.L. Gu, C.X. Long, E. Lobbestael, V. Baekelandt, J.M. Taymans, L. Sun, and H. Cai Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis J. Neurosci. 29 2009 13971 13980
71. Parkinson Study Group PRECEPT Investigators Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease Neurology 69 2007 1480 1490
72. X. Peng, R. Tehranian, P. Dietrich, L. Stefanis, and R.G. Perez Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells J. Cell. Sci. 118 2005 3523 3530
73. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E.S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W.G. Johnson, A.M. Lazzarini, R.C. Duvoisin, G. Di Iorio, L.I. Golbe, and R.L. Nussbaum Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
74. A.N. Pronin, A.J. Morris, A. Surguchov, and J.L. Benovic Synucleins are a novel class of substrates for G protein-coupled receptor kinases J. Biol. Chem. 275 2000 26515 26522
75. P.P. Pungaliya, Y. Bai, K. Lipinski, V.S. Anand, S. Sen, E.L. Brown, B. Bates, P.H. Reinhart, A.B. West, W.D. Hirst, and S.P. Braithwaite Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif PLoS One 5 2010 e13672
76. Z. Qi, W. Yang, Y. Liu, T. Cui, H. Gao, C. Duan, L. Lu, C. Zhao, H. Zhao, and H. Yang Loss of PINK1 function decreases PP2A activity and promotes autophagy in dopaminergic cells and a murine model Neurochem. Int. 59 2011 572 581
77. H. Qing, W. Wong, E.G. McGeer, and P.L. McGeer Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications Biochem. Biophys. Res. Commun. 387 2009 149 152
78. D. Ramonet, J.P. Daher, B.M. Lin, K. Stafa, J. Kim, R. Banerjee, M. Westerlund, O. Pletnikova, L. Glauser, L. Yang, Y. Liu, D.A. Swing, M.F. Beal, J.C. Troncoso, J.M. McCaffery, N.A. Jenkins, N.G. Copeland, D. Galter, B. Thomas, M.K. Lee, T.M. Dawson, V.L. Dawson, and D.J. Moore Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2 PLoS One 6 2011 e18568
79. N. Ramsden, J. Perrin, Z. Ren, B.D. Lee, N. Zinn, V.L. Dawson, D. Tam, M. Bova, M. Lang, G. Drewes, M. Bantscheff, F. Bard, T.M. Dawson, and C. Hopf Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons ACS Chem. Biol. 6 2011 1021 1028
80. R. Ricciarelli, A. Tasinato, S. Clement, N.K. Ozer, D. Boscoboinik, and A. Azzi Alpha-tocopherol specifically inactivates cellular protein kinase C alpha by changing its phosphorylation state Biochem. J. 334 Pt. 1 1998 243 249
81. C.A. Ross, and M.A. Poirier Protein aggregation and neurodegenerative disease Nat. Med. 10 Suppl. 2004 S10 S17
82. M.S. Saporito, E.M. Brown, M.S. Miller, and S. Carswell CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo J. Pharmacol. Exp. Ther. 288 1999 421 427
83. M.S. Saporito, R.L. Hudkins, and A.C. Maroney Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases Prog. Med. Chem. 40 2002 23 62
84. M.S. Saporito, B.A. Thomas, and R.W. Scott MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo J. Neurochem. 75 2000 1200 1208
85. A. Saraf, D.M. Virshup, and S. Strack Differential expression of the B'beta regulatory subunit of protein phosphatase 2A modulates tyrosine hydroxylase phosphorylation and catecholamine synthesis J. Biol. Chem. 282 2007 573 580
86. A.H. Schapira Progress in neuroprotection in Parkinson's disease Eur. J. Neurol. 15 Suppl. 1 2008 5 13
87. J. Schwarz Rationale for dopamine agonist use as monotherapy in Parkinson's disease Curr. Opin. Neurol. 16 Suppl. 1 2003 S27 S33
88. J.E. Sheppeck II, C.M. Gauss, and A.R. Chamberlin Inhibition of the Ser-Thr phosphatases PP1 and PP2A by naturally occurring toxins Bioorg. Med. Chem. 5 1997 1739 1750
89. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, M.R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy, and K. Gwinn-Hardy Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841
90. E. Sontag, C. Hladik, L. Montgomery, A. Luangpirom, I. Mudrak, E. Ogris, and C.L. White Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis J. Neuropathol. Exp. Neurol. 63 2004 1080 1091
91. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
92. S. Strack, J.T. Cribbs, and L. Gomez Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival J. Biol. Chem. 279 2004 47732 47739
93. E. Tappan, and A.R. Chamberlin Activation of protein phosphatase 1 by a small molecule designed to bind to the enzyme's regulatory site Chem. Biol. 15 2008 167 174
94. I.R. Taravini, M. Chertoff, E.G. Cafferata, J. Courty, M.G. Murer, F.J. Pitossi, and O.S. Gershanik Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats Mol. Neurodegener. 6 2011 40
95. E.M. Valente, P.M. Abou-Sleiman, V. Caputo, M.M. Muqit, K. Harvey, S. Gispert, Z. Ali, D. Del Turco, A.R. Bentivoglio, D.G. Healy, A. Albanese, R. Nussbaum, R. Gonzalez-Maldonado, T. Deller, S. Salvi, P. Cortelli, W.P. Gilks, D.S. Latchman, R.J. Harvey, B. Dallapiccola, G. Auburger, and N.W. Wood Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science 304 2004 1158 1160
96. C.H. van Dyck, P.N. Tariot, B. Meyers, and E. Malca Resnick A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease Alzheimer Dis. Assoc. Disord. 21 2007 136 143
97. D.M. Virshup, and S. Shenolikar From promiscuity to precision: protein phosphatases get a makeover Mol. Cell. 33 2009 537 545
98. M. Voronkov, S.P. Braithwaite, and J.B. Stock Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease Future Med. Chem. 3 2011 821 833
99. W. Wang, L. Shi, Y. Xie, C. Ma, W. Li, X. Su, S. Huang, R. Chen, Z. Zhu, Z. Mao, Y. Han, and M. Li SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease Neurosci. Res. 48 2004 195 202
100. P.J. Webber, A.D. Smith, S. Sen, M.B. Renfrow, J.A. Mobley, and A.B. West Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities J. Mol. Biol. 412 2011 94 110
101. A.B. West, D.J. Moore, S. Biskup, A. Bugayenko, W.W. Smith, C.A. Ross, V.L. Dawson, and T.M. Dawson Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc. Natl. Acad. Sci. USA 102 2005 16842 16847
102. M. Westerlund, A.C. Belin, A. Anvret, P. Bickford, L. Olson, and D. Galter Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease Neuroscience 152 2008 429 436
103. B. Winner, H.L. Melrose, C. Zhao, K.M. Hinkle, M. Yue, C. Kent, A.T. Braithwaite, S. Ogholikhan, R. Aigner, J. Winkler, M.J. Farrer, and F.H. Gage Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice Neurobiol. Dis. 41 2010 706 716
104. Y.H. Xu, Y. Sun, H. Ran, B. Quinn, D. Witte, and G.A. Grabowski Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models Mol. Genet. Metab. 102 2011 436 447
105. C. Yao, R. El Khoury, W. Wang, T.A. Byrd, E.A. Pehek, C. Thacker, X. Zhu, M.A. Smith, A.L. Wilson-Delfosse, and S.G. Chen LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease Neurobiol. Dis. 40 2010 73 81
106. H.J. Yeh, Y.Y. He, J. Xu, C.Y. Hsu, and T.F. Deuel Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury J. Neurosci. 18 1998 3699 3707
107. H. Yun, H.Y. Heo, H.H. Kim, N. DooKim, and W. Seol Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein Bioorg. Med. Chem. Lett. 21 2011 2953 2957
108. J.J. Zarranz, J. Alegre, J.C. Gomez-Esteban, E. Lezcano, R. Ros, I. Ampuero, L. Vidal, J. Hoenicka, O. Rodriguez, B. Atares, V. Llorens, E. Gomez Tortosa, T. del Ser, D.G. Munoz, and J.G. de Yebenes The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann. Neurol. 55 2004 164 173
109. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer. 9 2009 28 39
110. H. Zhou, C. Huang, J. Tong, W.C. Hong, Y.J. Liu, and X.G. Xia Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake Int. J. Biol. Sci. 7 2011 753 761
111. X.W. Zhou, J.A. Gustafsson, H. Tanila, C. Bjorkdahl, R. Liu, B. Winblad, and J.J. Pei Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A Neurobiol. Dis. 31 2008 386 394
112. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R.J. Uitti, D.B. Calne, A.J. Stoessl, R.F. Pfeiffer, N. Patenge, I.C. Carbajal, P. Vieregge, F. Asmus, B. Muller-Myhsok, D.W. Dickson, T. Meitinger, T.M. Strom, Z.K. Wszolek, and T. Gasser Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 44 2004 601 607